The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer–Alliance for Clinical Trials in Oncology–International Society of Geriatric Oncology Position Article
Open accessAbstract
Selecting the most appropriate end points for clinical trials is important to assess the value of new treatment strategies. Well-established end points for clinical research exist in oncology but may not be as relevant to the older cancer population because of competing risks of death and potentially increased impact of therapy on global functioning and quality of life. This article discusses specific clinical end points and their advantages and disadvantages for older individuals. Randomized or single-arm phase II trials can provide insight into the range of efficacy and toxicity in older populations but ideally need to be confirmed in phase III trials, which are unfortunately often hindered by the severe heterogeneity of the older cancer population, difficulties with selection bias depending on inclusion criteria, physician perception, and barriers in willingness to participate. All clinical trials in oncology should be without an upper age limit to allow entry of eligible older adults. In settings where so-called standard therapy is not feasible, specific trials for older patients with cancer might be required, integrating meaningful measures of outcome. Not all questions can be answered in randomized clinical trials, and large observational cohort studies or registries within the community setting should be established (preferably in parallel to randomized trials) so that treatment patterns across different settings can be compared with impact on outcome. Obligatory integration of a comparable form of geriatric assessment is recommended in future studies, and regulatory organizations such as the European Medicines Agency and US Food and Drug Administration should require adequate collection of data on efficacy and toxicity of new drugs in fit and frail elderly subpopulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study
Hurria, A., Togawa, K., Mohile, S. G., Owusu, C., Klepin, H. D., Gross, C. P., Lichtman, S. M., Gajra, A., Bhatia, S., Katheria, V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7625 · Cited by 1,841
Self-citationUnderstanding the Treatment Preferences of Seriously Ill Patients
Fried, T. R., Bradley, E. H., Towle, V. R., & Allore, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa012528 · Cited by 1,522
Extermann, M., Boler, I., Reich, R. R., Lyman, G. H., Brown, R. H., DeFelice, J., Levine, R. M., Lubiner, E. T., Reyes, P., Schreiber, F. J., et al. (2012) · Cancer · doi:10.1002/cncr.26646 · Cited by 1,143
Self-citationParticipation of Patients 65 Years of Age or Older in Cancer Clinical Trials
Lewis, J. H., Kilgore, M. L., Goldman, D. P., Trimble, E. L., Kaplan, R., Montello, M. J., Housman, M. G., & Escarce, J. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.010 · Cited by 1,031
Composite Outcomes in Randomized Trials: Greater Precision But With Greater Uncertainty?
Freemantle, N., Calvert, M., Wood, J., Eastaugh, J., & Griffin, C. (2003) · JAMA · doi:10.1001/jama.289.19.2554 · Cited by 783
Section XXIV. Partition Chromatographs
(2009) · Biotechnology · doi:10.1201/9781420084498-31 · Cited by 590
Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.002 · Cited by 588
Statistical Principles for Clinical Trials
Kay, R. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600201 · Cited by 573
Cited by
Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L. G., Extermann, M., Falandry, C., Artz, A., Brain, E., Colloca, G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8347 · Cited by 1,831
Self-citationChemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Casulo, C., Byrtek, M., Dawson, K. L., Zhou, X., Farber, C. M., Flowers, C. R., Hainsworth, J. D., Maurer, M. J., Cerhan, J. R., Link, B. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7534 · Cited by 850
Sedrak, M. S., Freedman, R. A., Cohen, H. J., Muss, H. B., Jatoi, A., Klepin, H. D., Wildes, T. M., Le‐Rademacher, J. G., Kimmick, G. G., Tew, W. P., et al. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21638 · Cited by 471
Self-citationHurria, A., Levit, L. A., Dale, W., Mohile, S. G., Muss, H. B., Fehrenbacher, L., Magnuson, A., Lichtman, S. M., Bruinooge, S. S., Soto-Perez-de-Celis, E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0319 · Cited by 419
Self-citation
Metadata
- Authors
- Wildiers, H., Mauer, M., Pallis, A., Hurria, A., Mohile, S. G., Luciani, A., Curigliano, G., Extermann, M., Lichtman, S. M., Ballman, K., Cohen, H. J., Muss, H., & Wedding, U.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-10-10
- Volume
- 31
- Issue
- 29
- Pages
- 3711-3718
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156875127
- Cited by
- 322
- References
- 39
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer–Alliance for Clinical Trials in Oncology–International Society of Geriatric Oncology Position Article. https://app.cochat.ai/papers/10.1200/jco.2013.49.6125
- The paper
- Wildiers, H., Mauer, M., Pallis, A., Hurria, A., Mohile, S. G., Luciani, A., Curigliano, G., Extermann, M., Lichtman, S. M., Ballman, K., Cohen, H. J., Muss, H., & Wedding, U. (2013). End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer–Alliance for Clinical Trials in Oncology–International Society of Geriatric Oncology Position Article. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.49.6125
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.